[go: up one dir, main page]

NO20016053L - IL-8 reseptor-antagonister - Google Patents

IL-8 reseptor-antagonister

Info

Publication number
NO20016053L
NO20016053L NO20016053A NO20016053A NO20016053L NO 20016053 L NO20016053 L NO 20016053L NO 20016053 A NO20016053 A NO 20016053A NO 20016053 A NO20016053 A NO 20016053A NO 20016053 L NO20016053 L NO 20016053L
Authority
NO
Norway
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016053A
Other languages
English (en)
Other versions
NO20016053D0 (no
Inventor
Katherine Louisa Widdowson
Daniel Frank Veber
Anthony Joseph Jurewicz
Melvin C Rutledge
Robert Philip Hertzberg
Gregory Martin Benson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016053L publication Critical patent/NO20016053L/no
Publication of NO20016053D0 publication Critical patent/NO20016053D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
NO20016053A 1999-06-16 2001-12-11 IL-8 reseptor-antagonister NO20016053D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13967599P 1999-06-16 1999-06-16
PCT/US2000/016499 WO2000076495A1 (en) 1999-06-16 2000-06-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20016053L true NO20016053L (no) 2001-12-11
NO20016053D0 NO20016053D0 (no) 2001-12-11

Family

ID=22487790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20016053A NO20016053D0 (no) 1999-06-16 2001-12-11 IL-8 reseptor-antagonister

Country Status (20)

Country Link
EP (1) EP1185261A4 (no)
JP (1) JP2003501459A (no)
KR (1) KR20020010709A (no)
CN (1) CN1355697A (no)
AR (1) AR030391A1 (no)
AU (1) AU766083B2 (no)
BR (1) BR0010802A (no)
CA (1) CA2377341A1 (no)
CO (1) CO5200760A1 (no)
CZ (1) CZ20014471A3 (no)
HK (1) HK1044483A1 (no)
HU (1) HUP0201571A3 (no)
IL (1) IL145761A0 (no)
MX (1) MXPA01013004A (no)
NO (1) NO20016053D0 (no)
NZ (1) NZ514695A (no)
PL (1) PL352232A1 (no)
TR (1) TR200103680T2 (no)
WO (1) WO2000076495A1 (no)
ZA (1) ZA200109479B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521479B2 (en) * 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
CN1671378A (zh) * 2002-08-01 2005-09-21 神经研究公司 用于治疗对抗血管生成疗法有应答的疾病的化合物
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1745032B1 (en) * 2004-05-12 2013-07-31 Merck Sharp & Dohme Corp. CXCR1 and CXCR2 chemokine antagonists
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
AU2005299771A1 (en) 2004-10-21 2006-05-04 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
KR20070100894A (ko) 2005-01-19 2007-10-12 브리스톨-마이어스 스큅 컴퍼니 혈전색전성 장애 치료용 ｐ2ｙ1 수용체 억제제로서의2-페녹시-ｎ-(1,3,4-티아디졸-2-일)피리딘-3-아민 유도체및 관련 화합물
WO2006089871A2 (en) * 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
MX2007016501A (es) 2005-06-27 2008-03-06 Squibb Bristol Myers Co Antagonistas heterociclicos n-enlazados del receptor de p2y1, utiles en el tratamiento de condiciones tromboticas.
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7700620B2 (en) 2005-06-27 2010-04-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
JP2008184403A (ja) * 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
KR100982661B1 (ko) * 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
KR100970940B1 (ko) * 2010-05-03 2010-07-20 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로 함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및 이를 이용한 말라리아 치료방법
US10093617B1 (en) 2015-10-30 2018-10-09 Sumitomo Chemical Company, Limited Method for producing 2-amino-4-substituted phenol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921120B (en) * 1991-02-19 1993-01-27 Smithkline Beecham Corp Cytokine inhibitors
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
WO2000016768A1 (en) * 1998-09-18 2000-03-30 Smithkline Beecham Corporation Cxcr2 inhibitors and pmn adhesion and t-cell chemotaxis

Also Published As

Publication number Publication date
JP2003501459A (ja) 2003-01-14
KR20020010709A (ko) 2002-02-04
BR0010802A (pt) 2002-02-19
TR200103680T2 (tr) 2002-07-22
ZA200109479B (en) 2002-11-18
WO2000076495A1 (en) 2000-12-21
AR030391A1 (es) 2003-08-20
EP1185261A4 (en) 2004-02-25
AU766083B2 (en) 2003-10-09
CA2377341A1 (en) 2000-12-21
EP1185261A1 (en) 2002-03-13
HUP0201571A3 (en) 2002-11-28
CZ20014471A3 (cs) 2002-08-14
HUP0201571A2 (en) 2002-08-28
NO20016053D0 (no) 2001-12-11
CN1355697A (zh) 2002-06-26
IL145761A0 (en) 2002-07-25
AU5741300A (en) 2001-01-02
PL352232A1 (en) 2003-08-11
HK1044483A1 (zh) 2002-10-25
NZ514695A (en) 2004-05-28
MXPA01013004A (es) 2002-07-30
CO5200760A1 (es) 2002-09-27

Similar Documents

Publication Publication Date Title
NO20001100D0 (no) IL-8 reseptorantagonister
NO20025754L (no) IL-8 Reseptor-antagonister
DE60216229D1 (de) Il-8-rezeptorantagonisten
NO20016053D0 (no) IL-8 reseptor-antagonister
ATE299698T1 (de) Il-8 rezeptor antagonisten
DE60126480D1 (de) Il-8 rezeptor-antagonisten
NO20016052L (no) IL-8-reseptor-antagonister
ATE381330T1 (de) Il-8 rezeptor-antagonisten
DK1180028T3 (da) IL-8-receptorantagonister
NO20024554D0 (no) IL-8 reseptorantagonister
DE69831413D1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20015774D0 (no) IL-8 reseptorantagonister
MA25659A1 (fr) Antagonistes recepteurs il-8
NO20016102L (no) IL-8 reseptorantagonister
NO20016065L (no) IL-8-reseptor-antagonister
NO20024366L (no) IL-8 reseptorantagonister
NO20010353D0 (no) IL-8 reseptor-antagonist
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application